Results 191 to 200 of about 92,728 (309)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Spontaneous Tumor Lysis Syndrome as the Initial Presentation of Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Clin Med Insights Case Rep
Asfaw MD, Mengistie CT, Azale AW, Gebre ME, Assefa AB, Deye FG, Andargie DG.   +6 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. [PDF]

Blood Adv
Castonguay M, Anderson MA, Thompson P, Seymour JF.   +3 more
europepmc   +1 more source

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias

Cancer Science, EarlyView.
Schematic illustration of the mechanisms by which the natural quassinoid brusatol induces apoptosis in myeloid leukemias and enhances venetoclax efficacy via p53‐dependent apoptosis and mitochondrial dysfunction. ABSTRACT While venetoclax‐based combinations have shown promising results in acute myeloid leukemia (AML), the remission duration is ...
Shin‐ichiro Kawaguchi, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Ken Suzaki, Susumu Goyama, Chiyoko Kato, Eiji Sakashita, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda   +11 more
wiley   +1 more source

Unusual Nasopharyngeal Localization of Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Cureus
Fadi M, Anajar S, Chahdi H, Lahlou FA, Bouanani N.   +4 more
europepmc   +1 more source

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

Cancer Science, EarlyView.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source

Concurrent hepatic cirrhosis and chronic lymphocytic leukemia: a challenging coexistence: a case report. [PDF]

J Med Case Rep
Mahani FK, Nezhad NZ, Ghaderi R, Jafari E, Khazaeli M, Kermanshahaninejad SO, Shamsinejad B.   +6 more
europepmc   +1 more source

Input Visualizations to Track Health Data by Older Adults with Multiple Chronic Conditions

Computer Graphics Forum, EarlyView.
Abstract Older adults living with multiple chronic conditions (MCC) can considerably benefit from collecting and reflecting on their health data. Many older adults collect their health data using various approaches, such as digital tools or handwritten notebooks.
Shri Harini Ramesh, Foroozan Daneshzand, Matteo Sotelo, Mahsa Sinaei, Fateme Rajabiyazdi   +4 more
wiley   +1 more source

Auer Rod-Like Inclusions in Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Clin Case Rep
Zhang T, Xie L.
europepmc   +1 more source